Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protein. The Abl inhibitors imatinib, nilotinib and dasatinib are currently used to treat CML, but resistance to these inhibitors is a significant clinical problem. The kinase inhibitor bosutinib has shown efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Levinson, Nicholas M., Boxer, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320885/
https://www.ncbi.nlm.nih.gov/pubmed/22493660
http://dx.doi.org/10.1371/journal.pone.0029828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320885/
https://www.ncbi.nlm.nih.gov/pubmed/22493660
http://dx.doi.org/10.1371/journal.pone.0029828

Ejemplares similares